Ali Health reaches strategic cooperation with Tengrui Pharmaceutical and Pegasus Biotechnology.

On July 17th, Ali Health, Shanghai Tengrui Pharmaceutical Co., Ltd., and PegBio Pharmaceutical Co., Ltd. jointly announced a strategic cooperation. The core product of this cooperation, Paidacong, is a type 1 GLP-1RA new drug independently developed in China. PegBio Pharmaceutical Co. is responsible for independent research and development, while Tengrui Pharmaceutical Co. is responsible for commercial promotion. According to the plan, Paidacong will be launched on Ali Health platform soon.